One or Two Immune Checkpoint Inhibitors?

Caroline Robert; Emilie Lanoy; Benjamin Besse

doi:10.1016/j.ccell.2019.11.005

One or Two Immune Checkpoint Inhibitors?

Caroline Robert, Emilie Lanoy, Benjamin Besse

Résultats de recherche: Contribution à un journal › !!Comment/debate

10 Citations (Scopus)

Résumé

The combination of ipilimumab and nivolumab was evaluated versus standard treatments in melanoma and lung cancer. Analysis of these trials highlights the differences in outcomes and potential predictive biomarkers across tumor types as well as the multiple remaining questions concerning the optimal use of immune checkpoint inhibitors.

langue originale	Anglais
Pages (de - à)	579-581
Nombre de pages	3
journal	Cancer Cell
Volume	36
Numéro de publication	6
Les DOIs	https://doi.org/10.1016/j.ccell.2019.11.005
état	Publié - 9 déc. 2019

Accès au document

10.1016/j.ccell.2019.11.005

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{f0cee984603a419d9797054dca3184b0,

title = "One or Two Immune Checkpoint Inhibitors?",

abstract = "The combination of ipilimumab and nivolumab was evaluated versus standard treatments in melanoma and lung cancer. Analysis of these trials highlights the differences in outcomes and potential predictive biomarkers across tumor types as well as the multiple remaining questions concerning the optimal use of immune checkpoint inhibitors.",

author = "Caroline Robert and Emilie Lanoy and Benjamin Besse",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = dec,

day = "9",

doi = "10.1016/j.ccell.2019.11.005",

language = "English",

volume = "36",

pages = "579--581",

journal = "Cancer Cell",